Translarna by PTC Therapeutics: Awaiting Another EU Regulatory Review for Muscular Dystrophy Treatment

PTC Therapeutics, Translarna, muscular dystrophy, EU review, regulatory approval, Duchenne muscular dystrophy (DMD), European Medicines Agency (EMA), ataluren, rare disease treatment.

Johnson & Johnson Expands into IL-13 and TSLP Market with Strategic Acquisition

Johnson & Johnson, I&I acquisition, IL-13, TSLP, competitive market, strategic expansion, pharmaceutical industry, biologics, inflammatory diseases.

Novo Nordisk’s Wegovy Shines as a Promising Obesity Treatment: A 4-Year Analysis

Novo Nordisk, Wegovy, obesity treatment, weight loss, 4-year data, clinical trials, blockbuster drug, GLP-1 receptor agonist, FDA approval, semaglutide.

Innovent Scores Phase 3 Success with Lilly’s Pioneering Obesity Drug for Diabetes Management

Innovent Biologics, Eli Lilly, obesity drug, diabetes management, phase 3 trials, collaboration, metabolic disorders, weight loss, glucose control, next-generation therapy.

Revolutionizing Public Health: CBER’s Peter Marks and the Vision to Reduce FDA Visits

CBER, Peter Marks, FDA, public health, healthcare innovation, regulatory affairs, biologics, vaccines, medical devices, preventive measures.

What is the difference between prime editing and CRISPR/Cas9

The difference between Prime Editing and CRISPR/Cas9 lies in their mechanisms of editing DNA, their efficiency, precision, and the types of genetic modifications they can achieve. Mechanism of Editing Efficiency and Precision Types of Genetic Modifications In summary, while both Prime Editing and CRISPR/Cas9 are groundbreaking genome editing tools, Prime Editing offers a more precise […]